Hiller, J. G. et al. Perioperative occasions affect most cancers recurrence threat after surgical procedure. Nat. Rev. Clin. Oncol. 15, 205–218 (2018).
Reya, T. et al. Stem cells, most cancers, and most cancers stem cells. Nature 414, 105–111 (2001).
Barbato, L. et al. Most cancers stem cells and concentrating on methods. Cells 8, 926 (2019).
Batlle, E. & Clevers, H. Most cancers stem cells revisited. Nat. Med. 23, 1124–1134 (2017).
Prager, B. C. et al. Most cancers stem cells: the architects of the tumor ecosystem. Cell Stem Cell 24, 41–53 (2019).
Chu, X. et al. Most cancers stem cells: advances in information and implications for most cancers remedy. Sign Transduct. Goal Ther. 9, 170 (2024).
Gilboa, E. The promise of most cancers vaccines. Nat. Rev. Most cancers 4, 401–411 (2004).
Blass, E. & Ott, P. A. Advances within the improvement of customized neoantigen-based therapeutic most cancers vaccines. Nat. Rev. Clin. Oncol. 18, 215–229 (2021).
Ruiu, R. et al. Most cancers stem cell immunology and immunotherapy: harnessing the immune system in opposition to most cancers’s supply. Prog. Mol. Biol. Transl. Sci. 164, 119–188 (2019).
Ning, N. et al. Most cancers stem cell vaccination confers important antitumor immunity. Most cancers Res. 72, 1853–1864 (2012).
Hu, Y. et al. Therapeutic efficacy of most cancers stem cell vaccines within the adjuvant setting. Most cancers Res. 76, 4661–4672 (2016).
Klein, O. et al. Melanoma vaccines: developments over the previous 10 years. Professional Rev. Vaccines 10, 853–873 (2011).
Quaglino, E., Conti, L. & Cavallo, F. Breast most cancers stem cell antigens as targets for immunotherapy. Semin. Immunol. 47, 101386 (2020).
Hassani, N. A. et al. Most cancers immunotherapy by way of concentrating on most cancers stem cells utilizing vaccine nanodiscs. Nano Lett. 20, 7783–7792 (2020).
Ginestier, C. et al. ALDH1 is a marker of regular and malignant human mammary stem cells and a predictor of poor scientific end result. Cell Stem Cell 1, 555–567 (2007).
Silva, I. A. et al. Aldehyde dehydrogenase together with CD133 defines angiogenic ovarian most cancers stem cells that portend poor affected person survival. Most cancers Res. 71, 3991–4001 (2011).
Wang, Q. et al. Tamoxifen enhances stemness and promotes metastasis of ERα36+ breast most cancers by upregulating ALDH1A1 in most cancers cells. Cell Res. 28, 336–358 (2018).
Liu, C. et al. ALDH1A1 exercise in tumor-initiating cells remodels myeloid-derived suppressor cells to advertise breast most cancers development. Most cancers Res. 81, 5919–5934 (2021).
Lizee, G. et al. Management of dendritic cell cross-presentation by the most important histocompatibility advanced class I cytoplasmic area. Nat. Immunol. 4, 1065–1073 (2003).
Samie, M. & Cresswell, P. The transcription issue TFEB acts as a molecular change that regulates exogenous antigen-presentation pathways. Nat. Immunol. 16, 729–736 (2015).
Han, D. et al. Anti-tumour immunity managed by means of mRNA m6A methylation and YTHDF1 in dendritic cells. Nature 566, 270–274 (2019).
Min, L. H. Cationic lipids-mediated dual-targeting of each dendritic cells and tumor cells for potent most cancers immunotherapy. Adv. Funct. Mater. 33, 2306752 (2023).
Hu, M. et al. Immunogenic hybrid nanovesicles of liposomes and tumor-derived nanovesicles for most cancers immunochemotherapy. ACS Nano 15, 3123–3138 (2021).
Gabrilovich, D. I., Ostrand, R. S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253–268 (2012).
Engblom, C., Pfirschke, C. & Pittet, M. J. The function of myeloid cells in most cancers therapies. Nat. Rev. Most cancers 16, 447–462 (2016).
Xiao, Z., Todd, L. & Huang, L. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in stable tumors. Nat. Commun. 14, 510 (2023).
Lakins, M. A., Ghorani, E. & Munir, H. Most cancers-associated fibroblasts induce antigen-specific deletion of CD8+ T cells to guard tumour cells. Nat. Commun. 9, 948 (2018).
Hong, J. et al. T‐cell‐derived nanovesicles for most cancers immunotherapy. Adv. Mater. 33, 2101110 (2021).
Trevaskis, N. L., Kaminskas, L. M. & Porter, C. J. From sewer to saviour—concentrating on the lymphatic system to advertise drug publicity and exercise. Nat. Rev. Drug. Discov. 14, 781–803 (2015).
Chen, L. et al. Bacterial cytoplasmic membranes synergistically improve the antitumor exercise of autologous most cancers vaccines. Sci. Transl. Med. 13, 601 (2021).
von Andrian, U. H. & Mempel, T. R. Homing and mobile site visitors in lymph nodes. Nat. Rev. Immunol. 3, 867–878 (2003).
Clatworthy, M. R. et al. Immune complexes stimulate CCR7-dependent dendritic cell migration to lymph nodes. Nat. Med. 20, 1458–1463 (2014).
Lin, W. et al. Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors by way of selling MHC-I degradation. Nat. Commun. 14, 265 (2023).
You, Q. et al. m6A reader YTHDF1-targeting engineered small extracellular vesicles for gastric most cancers remedy by way of epigenetic and immune regulation. Adv. Mater. 35, e2204910 (2023).
Cui, C. et al. A lysosome-targeted DNA nanodevice selectively targets macrophages to attenuate tumours. Nat. Nanotechnol. 16, 1394–1402 (2021).
Zehner, M. et al. The translocon protein Sec61 mediates antigen transport from endosomes within the cytosol for cross-presentation to CD8+ T cells. Immunity 42, 850–863 (2015).
McClements, L. et al. Concentrating on treatment-resistant breast most cancers stem cells with FKBPL and its peptide by-product, AD-01, by way of the CD44 pathway. Clin. Most cancers Res. 19, 3881–3893 (2013).
Shen, S. et al. A nanotherapeutic technique to beat chemotherapeutic resistance of most cancers stem-like cells. Nat. Nanotechnol. 16, 104–113 (2021).
Dieter, S. M. et al. Distinct kinds of tumor-initiating cells kind human colon most cancers tumors and metastases. Cell Stem Cell 9, 357–365 (2011).
Zhang, W. C. et al. Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to advertise non-small cell lung most cancers development. Nat. Commun. 7, 11702 (2016).
Nguyen, L. N. M. et al. The exit of nanoparticles from stable tumours. Nat. Mater. 22, 1261–1272 (2023).
Fu, A. et al. Tumor-resident intracellular microbiota promotes metastatic colonization in breast most cancers. Cell 185, 1356–1372 (2022).
Wang, Okay. Biomimetic nanovaccine-mediated multivalent IL-15 self-transpresentation (MIST) for potent and protected most cancers immunotherapy. Nat. Commun. 14, 6748 (2023).
Zhai, Y. et al. T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for most cancers immunotherapy. Nat. Nanotechnol. 16, 1271–1280 (2021).
Krishnan, N. et al. A modular method to enhancing cell membrane-coated nanoparticle performance utilizing genetic engineering. Nat. Nanotechnol. 19, 345–353 (2024).
Elsadek, B. & Kratz, F. Influence of albumin on drug delivery-new functions on the horizon. J. Management. Launch 157, 4–28 (2012).
Track, Y. et al. Albumin nanoparticle containing a PI3Kγ inhibitor and paclitaxel together with α-PD1 induces tumor remission of breast most cancers in mice. Sci. Transl. Med. 14, eabl3649 (2022).
Zhang, S. et al. Kind 1 typical dendritic cell destiny and performance are managed by DC-SCRIPT. Sci. Immunol. 6, eabf4432 (2021).
Giampazolias, E. et al. Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and most cancers immunity. Cell 184, 4016–4031. e22 (2021).
Canton, J. et al. The receptor DNGR-1 alerts for phagosomal rupture to advertise cross-presentation of dead-cell-associated antigens. Nat. Immunol. 22, 140–153 (2021).
Roney, Okay. Bone marrow-derived dendritic cells. Strategies Mol. Biol. 1960, 57–62 (2019).
Assouvie, A., Daley-Bauer, L. P. & Rousselet, G. Rising murine bone marrow-derived macrophages. Strategies Mol. Biol. 1784, 29–33 (2018).
Hui, Y. et al. Collection of DNA aptamers in opposition to DC-SIGN protein. Mol. Cell. Biochem. 306, 71–77 (2007).
Ghosh, M. & Shapiro, L. H. In vitro Ag cross-presentation and in vivo Ag cross-presentation by dendritic cells within the mouse. Bio-Protocol 2, e305 (2012).
Liu, C. et al. A nanovaccine for antigen self-presentation and immunosuppression reversal as a customized most cancers immunotherapy technique. Nat. Nanotechnol. 17, 531–540 (2022).
